
FDA Accepts Two Applications for Merck’s DIFICID® (fidaxomicin) to Treat Children Aged Six Months Up to 18 years with Clostridium difficile Infections
Dateline City: KENILWORTH, N.J. DIFICID® Pediatric Filings Receive Priority Review Classification KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK),…







.jpg)







.jpg)





